Recurrent Tumor Therapy
Recurrent Tumor Therapy - Related Videos
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
0 Views •
Cited by 15 •
2014
A novel methodology that is employed for the treatment of recurrent glioblastomas is described. This treatment approach employs the application of alternating electric tumor treating fields (TTFields), known as TTF Therapy in combination with bevacizumab, a targeted agent that is currently FDA approved as monotherapy.
03:10
Treatment of Brain Tumors in a Mouse Model Using Sonodynamic Therapy
0 Views •
2025
Source: Mess, G., et al. Sonodynamic Therapy for the Treatment of Glioblastoma Multiforme in a Mouse Model Using a Portable Benchtop Focused Ultrasound System. J. Vis. Exp. (2023)This video demonstrates a protocol for performing sonodynamic therapy on a brain tumor in a mouse model using magnetic resonance-guided focused ultrasound (MRgFUS). A sonosensitizer precursor is administered prior to treatment, which accumulates in tumor cells and is activated by focused ultrasound to produce reactive...
04:13
An Adjuvant Therapy in a Mouse Model with an Incompletely Resected Subcutaneous Tumor
0 Views •
2025
This video illustrates testing of adjuvant or additional therapy in a mouse model with incompletely resected subcutaneous tumors. The partially tumor-resected mouse is treated with an antibody targeting the anti-cytotoxic protein of T regulatory cells, potentially reducing tumor regrowth and suggesting effective adjuvant therapy.
11:09
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
0 Views •
Cited by 104 •
2010
Luciferase-modified human brain tumor xenografts can be established intracranially in athymic mice, with subsequent monitoring of tumor growth and response to therapy using bioluminescence imaging. In combination with survival analysis, bioluminescence monitoring is an essential research tool for pre-clinical testing of therapies being considered for treating brain tumors.
10:13
A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
0 Views •
Cited by 29 •
2015
Many types of human brain tumors are localized to specific regions within the brain and are difficult to grow in culture. This protocol addresses the role of tumor microenvironment and investigates new drug treatments by analyzing fluorescent primary brain tumor cells growing in an organotypic mouse brain slice.
FAQs
Imaging provides the initial assessment, but scans may not alone establish whether abnormal findings represent returning cancer or effects of earlier treatment. When feasible, clinicians obtain tissue or molecular information to clarify the underlying process. This distinction matters because the interpretation can change the treatment plan, including whether to consider surgery, radiation, systemic drugs, or another strategy.
A tumor that returns after an initial response may no longer respond to the same approach, making resistance a central therapeutic concern. Prior treatment history, tumor biology, and molecular findings help clinicians reassess which options remain appropriate. Studying these changes also supports research into why tumors evade treatment and how care can become more personalized.
Tumor location is especially important in neuro-oncology because cancer may infiltrate brain tissue that supports essential neurological functions. Clinicians therefore weigh potential tumor control against the need to preserve function, alongside tumor biology, previous treatment, and the patient’s condition. These factors help determine whether repeat surgery, radiation, systemic therapy, or a combined approach is suitable.
Combining modalities can address recurrent disease through different therapeutic approaches while adapting to the tumor’s location, biology, and prior treatment. Options may include repeat surgery, focused or external-beam radiation, systemic drugs, targeted therapies, or clinical trials. The overall strategy seeks to control growth while also relieving symptoms, preserving neurological function, and extending survival.
Evaluation begins with imaging to characterize the current abnormality and compare it with the prior disease course. When feasible, clinicians add tissue or molecular analysis to distinguish recurrence from treatment-related changes and to guide therapy. They then consider tumor location, biology, previous treatment, and patient condition when selecting an individualized management plan.
Clinical trials become relevant when clinicians are evaluating treatment options in the setting of recurrence, resistance, or limited standard approaches. They can provide access to investigational strategies while generating evidence about tumor biology and therapeutic response. Within neuro-oncology, trial participation also contributes to broader efforts to develop more personalized care for tumors affecting sensitive brain tissue.
Treatment success is not measured only by tumor control. Clinicians also consider whether therapy relieves symptoms, preserves neurological function, and extends survival. These outcomes reflect the distinctive challenges of treating cancer within or near sensitive brain tissue. The balance among them helps guide decisions when available treatments carry different potential benefits and burdens.